MVM seeks to fund healthcare innovation that enables the delivery of higher quality yet cost-effective medical care for the global markets
We maintain stringent criteria for the selection of our portfolio companies. While not all of these criteria need be satisfied in every instance, they form the basis for MVM’s investment decisions:
• A portfolio company must have plans to commercialise technologies that address unmet medical needs for large market opportunities.
Unmet medical need may refer to a medical condition for which there is no adequate treatment, therapy is too expensive, diagnosis is inaccurate, or the side effects of treatment limit its use. It may also refer to situations where the cost of medical management is higher than payers are willing to meet, or where providers cannot deliver current care profitably
• A portfolio company must have clearly differentiated technology that has strong prospects for durable protection against competition, provided by patents, high barriers to market entry (regulatory approval or a significant lead in development), statutory exclusivity or branding.
• A portfolio company must appreciate the importance of highly-skilled and talented managers capable of leading the company to achieve both near- and long-term milestones. In some instances, MVM may assist in recruiting experienced managers to augment the existing management team.
Once MVM has completed due diligence to its initial satisfaction, the terms under which MVM is prepared to invest will be set out in writing. If terms are agreed, MVM will coordinate the preparation of definitive legal agreements and the completion of outstanding due diligence items.
Should you be interested in meeting the MVM team to discuss your business and its capital needs, please contact Hugo Harrod at email@example.com or on +44 20 7557 7515 or Eric Bednarski at firstname.lastname@example.org or on +1 617 383 2102.